Not available
Quote | Cardiff Oncology (NASDAQ:TROV)
Last: | $1.19 |
---|---|
Change Percent: | -0.83% |
Open: | $1.19 |
Close: | $1.19 |
High: | $1.19 |
Low: | $1.16 |
Volume: | 166,427 |
Last Trade Date Time: | 05/07/2020 04:47:16 am |
News | Cardiff Oncology (NASDAQ:TROV)
Cardiff Oncology ( TROV ) (formerly Trovagene) inks an agreement with PoC Capital, LLC to fund the completion of its ongoing Phase 1b/2 clinical trial evaluating onvansertib, combined with Roche's Avastin (bevacizumab) and chemo regimen FOLFIRI, in patients with KRAS mutation-positive me...
TrovaGene (NASDAQ: TROV ): Q1 GAAP EPS of -$0.41. More news on: TrovaGene, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Message Board Posts | Cardiff Oncology (NASDAQ:TROV)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today a...
SAN DIEGO , May 6, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company developing its drug, onvansertib, to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga&...
SAN DIEGO , April 28, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, ...